ClinicalTrials.gg
CompletedNCT06744686Updated Nov 2, 2026

Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients With Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

A Phase 1 interventional study of HT-102 and HT-102 in Chronic Hepatitis B, sponsored by Suzhou HepaThera Biotech Co., Ltd.. Completed at 7 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Suzhou HepaThera Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jun 2023, registered Dec 2024).
Updated Nov 2, 2026Title changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
214th of 273
56 · median 120
Started
2023
with 28 others
Phase 1
50 of 375
16 open now
Registered
305th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 214th largest by enrollment of the 273 interventional ones that give a count, is one of 29 that started in 2023, is one of 50 in phase 1, and was the 305th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of HT-102 (BM012) Injection in Healthy Subjects and Hepatitis B e Antigen-Negative Patients with Chronic Hepatitis B Virus Infection: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Subcutaneous Injections, and Dose Escalation Phase 1 Clinical Study

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Participants SAD:

  • Male participants weighed ≥ 50.0 kg, female participants weighed ≥ 45.0 kg;
  • Participants were healthy individuals;
  • Participants promise to have no plans to have a child, donate sperm or eggs and voluntarily take effective non-drug measures during the trial and within 3 months after the end of the trial;

Participants with Chronic infection, MAD:

  • Chronic HBV infection, and HBeAg negative;
  • Patients who had received antiviral therapy for at least one year before screening and stabilization therapy with nucleoside (nucleotide) reverse transcriptase inhibitors for ≥ 3 months before screening (nucleoside (nucleotide) reverse transcriptase inhibitors;

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of active pathological hemorrhage or those with bleeding tendency, or those with a history of neurological disease;
  • Participants with major trauma or major surgery within 3 months before trial screening;
  • Participants with a history of drug allergy;
  • Participants who used any drugs before trial screening or are using any drugs, including vitamins and Chinese herbal medicines;
  • Participants with abnormal results of examination, laboratory test in the screening period which were judged as ;
  • Participants who cannot tolerate subcutaneous injection;
  • Patients with a previous clinical diagnosis of liver cirrhosis, or a history of alcoholic liver disease, liver disease, inherited metabolic liver disease, and other liver diseases;
  • Participants with a clinically significant acute infection;
  • Women who were pregnant or lactating or had a positive pregnancy test result;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Part A (Healthy participants administered with HT-102 or placebo)

    Healthy participants in all dose groups were randomly assigned to receive a single dose of HT-102 or placebo subcutaneously

    Drug: HT-102 · Drug: Placebo

  • Experimental
    Part B (Patients with CHB administered with HT-102 or placebo)

    Patients with chronic hepatitis B in all dose groups were randomly assigned to receive 5 dose of HT-102 or placebo subcutaneously every week.

    Drug: HT-102 · Drug: Placebo

Interventions

  • DrugHT-102

    50mg, 150mg, 300mg, 600mg

  • DrugHT-102

    50mg, 150mg, 300mg

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: From administration to the end of treatment at 8 weeks

  2. Time to Reach Maximum Plasma Concentration (Tmax)

    Time frame: From administration to the end of treatment at 8 weeks

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: From administration to the end of treatment o at 10 weeks

  2. Area Under the Plasma Concentration Versus Time Curve (AUC)

    Time frame: From administration to the end of treatment o at 10 weeks

  3. Apparent Terminal Elimination Half-life (T1/2)

    Time frame: From administration to the end of treatment o at 10 weeks

  4. Apparent Plasma Clearance (CL/F)

    Time frame: From administration to the end of treatment o at 10 weeks

  5. Apparent volume of distribution(Vd/F)

    Time frame: From administration to the end of treatment o at 10 weeks

  6. Change of Serum HBsAg From Baseline

    Time frame: From administration to the end of treatment o at 10 weeks

  7. Change of Serum HBV DNA From Baseline

    Time frame: From administration to the end of treatment o at 10 weeks

  8. Change of Serum HBV RNA From Baseline

    Time frame: From administration to the end of treatment o at 10 weeks

  9. Change of Serum HBcrAg From Baseline

    Time frame: From administration to the end of treatment o at 10 weeks

  10. Change of Serum HBcAb From Baseline

    Time frame: From administration to the end of treatment o at 10 weeks

  11. Titers of Anti-drug Antibody (ADA) to HT-102

    ADA analysis for predose and 8week (Part A) or 10weeks (Part B) postdose

    Time frame: From administration to the end of treatment o at 10 weeks

07

Study locations

7 sites
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian 350025, China
  • People's Hospital of Qingyuan
    Qingyuan, Guangdong 511518, China
  • Luoyang Central Hospital
    Luoyang, Henan 471000, China
  • The Sixth People's Hospital of Zhengzhou
    Zhengzhou, Henan 450015, China
  • Shandong Public Health Clinical Center
    Jinan, Shandong 250102, China
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality 200080, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 325035, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Mar 2024, 9 months.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 20, 2024
StartActual
Jun 12, 2023
Primary completionActual
Mar 12, 2024
CompletionActual
Jun 18, 2024
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Shanghai General Hospital · Shanghai, China
Show 1 removed
  • Shanghai General Hospital · Shanghai, China
Nov 2, 2026
Title
Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients withWith Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added, 1 site removed
    Show site
    • Shanghai General Hospital · Shanghai, China
    Show 1 removed
    • Shanghai General Hospital · Shanghai, China
    Title Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients withWith Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06744686
Lead sponsor
Suzhou HepaThera Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Jun 12, 2023
Primary completion
Mar 12, 2024
Completion
Jun 18, 2024
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion